Monday, March 16, 2009

Emageon Merger Arbitrage - Update

On March 11th, 2009 a putative class action law suit was filed againat Emageon and AMICAS claiming that the Company breached its fudiciary duty when negotiating the merger. The plaintiffs seeks to enjoin the trasnaction. Both Emageon and AMICAS (and myself) believe the lawsuit is without merit. Nonetheless, the currently pending lawsuit could lengthen the time until closing.

Technology Solutions Liquidation - Update

Today, Technology Solutions Company (TICKER: TSCC) filed its preliminary proxy materials related to the Plan of Complete Liquidation and Dissolution of the Company. According to the plan (and consistent with my prior post and original Plan), the Company expects to make an initial liquidating distribution of at least $2/share immediately following shareholder approval of the Plan. In addition, the Company stated that the initial liquidating distribution could be higher, depending on when the non-cash assets are monetized. Also, as indicated in the Plan the Company intends to make additional liquidating distributions to the shareholders. Total distributions are expected to range from $2.39 to $2.69 per share in cash, which is inclusive of the initial liquidating distribution of $2/share. The stock closed up to $2.30 today, or 8.49% above the $2.12 price mentioned in my original post last week.

The company anticipates that a majority of the remaining distributions will be made by the end of 2009.

Summary of Liquidation Estimets (Preliminary Proxy pg. 23)



The table above demonstrates that a considerable portion of the expected liquidation distributions will come from assets with highly ascertainable values. Over 78.8% of the total estimated assets (based upon the low estimate) is cash deposited at the Harris Bank in Chicago. The expected cash collections are primarily trade receivables due from various hospitals, which should be collected with virtually little problems.

The primary note collections are related entirely to two outstanding notes from the sale of the Company's subsidiary companies. The first note is payable by EnteGreat Solutions, LLC for the sale of the Company's SAP Practice. The total amount due under the note is $380,271, and is due April 29, 2009. The second note is payable by Valkre Solutions, Inc. for the sale of the Company's CVC Practice, and is due in two equal installments on March, 31st and June 30th 2009 for $135,918 (I suspect that these values, when added together, are slightly higher than the value indicated in the table because the Company discounted them). Moreover, the interest earned relates to interest payable on the cash balances on the Company's bank account. Collectively, these assets equal over 95.66% of the estimated realizable value of the Company's assets under the low estimate; these value should not change going forward, and if they do their effect on the ultimate distribution will be de minimis.

While the prelimary proxy materials do not provide detailed infomation on the assets underlying the "estimated sale of assets" category of their liquidation distribution estimates, the amount is most likely related to approximately $768,000 in capitalized software and development costs for the Company's Blue Ocean medical software, which reached technological feasibility during the 2nd quarter of FY 2008. I suspect that these assets will be sold relatively quickly due to a one line sentence in the Background portion of the preliminary proxy materials that states: "Since the announcement of the approval of the Plan of Dissolution by the Board, Mr. Silva-Craig has been approached by numerous parties with respect to the possible purchase of various assets of the Company." Also, as aside another party who is interested in effecting a reverse merger with the Company has contacted Mr. Silvia, a transaction which, if structured correctly, could lead to additional value for TSCC shareholders.

The only real uncertainty is related to the total estimated liabilities. I must admit that estimating the total amount of such expenses is totally beyond my level of competence. However, I believe a reasonable margin of safety is to increase the high estimate by 10-15%. Under such an assumption total estimated liabilities would range between $2,756,122.6 and $2,881,400.9. Thus, if the non-cash assets are sold for the average of the low and high estimate, or approximately $687,500, then the "likely" distribution could range between $2.36-$2.41/share, which is near the Company's low estimate. The 10-15% increase in high expenses, however, may be entirely unreasonable given that most of the estimated expenses are fixed. Therefore, if we simply use the Company's high estimate as a proxy for total expenses, then the "likely" estimated distribution is approximately $2.51/share, which represents a decent premium to my acquistion price of $2.12/share (approximately 18.39%, or 24.52% on an annualized basis if we assume distriubtions are made on or before December 31st, 2009).

Thursday, March 12, 2009

Roche/Genentech Merger

Today, Roche announced that it would acquire Genetech for $95/share in cash or $46.8 billion Genentech currently trades for $94. I will provide more details after I review the definitive merger agreement and other supplementary materials.

Gilead Sciences/CV Therepeutics Merger

Today, Gilead Sciences (TICKER: GILD) announced that it would acquire CV Therapeutics (TICKER: CVTX) for $20/share in cash or $1.4 billion. I will keep everyone updated on the transaction after I read the definitive merger agreement and other related proxy material. Currently, CVTX trades at a premium to the merger consideration, reflecting the Street's anticipation of another bidder or perhaps a bidding ware between GILD and Astellas tender offer at $16, which the CVTX Board recently rejected.

Return of the Net/Nets

Recent dislocations in US equity markets have caused a resurgence in the number of so called "net/nets." A "net/net" is simply a security whose market value is less than its net current asset value (NCAV), where net current asset value is defined as total current assets less total liabilities (i.e. both short-term and long-term). The term was coined by Benjamin Graham, Warren Buffett's mentor and teacher, who developed a very impressive investment record investing in such securities. The basic investment strategy was to purchase a diversified basket (perhaps 50 or more) of stocks trading at 2/3rds their NCAV and holding them until for about 3-5 years, or until they reached NCAV. The strategy generated annualized returns of approximately 20% per annum during the 20 or 30 some odd years in which Graham implemented the strategy. Unforunately, many of these "net/nets" dissapeared over the years, but now they are beginning to resuface. I conducted a recent scan and was able to identify over 700 securites trading well below their NCAV. Here are a few securities that appared on that list:

1. Tech Data Corporation (TICKER: TECD)
2. Arctic Cat (TICKER: ACAT)
3. Movado (TICKER: MOV)
4. Signet Jeweleres (TICKER: SIG)
5. Electro Scientific Industries (TICKER: EIO)
6. Natuzzi SpA (TICKER: NTZ)

I will begin to manually go through the list of 700 securities to weed out "defective" companies, and will report on any interesting securities that I find.

Emageon/AMICAS Tender Offer

My recent risk arbitrage in the Tender Offer of AMICAS for Emageon at $1.82/share seems to be rolling smoothly. The tender commenced as planned on March 5th, my shares have already been tendered, and the spread on the transaction has closed to $0.01 (the stock current trades at $1.81), which suggests the Streets overall confidence in the transaction. I have heard some discussion of potential deal problems related to the Escrow paymenet received from HSS, especially if HSS falls into bankruptcy. I need to look into these problems a little more closely.